IRVING, Texas, March 30 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced that seven (7) seasoned professional representatives with experience in equine product sales now support the Carrington(R) EquineVet(TM) advanced wound care product line. Clinical results demonstrate usefulness of products to equine veterinarians and horse owners.
(Photo: http://www.newscom.com/cgi-bin/prnh/20070330/DAF016-A
http://www.newscom.com/cgi-bin/prnh/20070330/DAF016-B )
The EquineVet(TM) line contains a core component in Carrington’s injectable biologic product, Acemannan Immunostimulant(TM) (AI), marketed under authorization from the United States Department of Agriculture (USDA), for the treatment of fibrosarcoma (a form of soft tissue cancer) in cats and dogs. AI has a polymeric backbone of acetylated mannan called Acemannan. Acemannan acts on cells in the immune system that release Tumor Necrosis Factor (TNF), Interleukin-1 (IL-1), Interleukin-6 (IL-6), triggers an increase in natural killer cell and cytotoxic T-Cell activity, potentiates cellular and humoral immunity, and increases the natural healing process.
Based on the known biological activity of polymeric acetylated mannans, and working with equine veterinarians, Carrington developed the EquineVet(TM) Acemannan Advanced Wound Therapy System. Products have been formulated to address the special wound care needs of horses. Hyper-granulation tissue (proud flesh) formation in extremity wounds of horses is a real problem for veterinarians involved in wound management, as is the length of time needed for healing and the appearance of abnormal tissue growth after healing.
Kirk Meares, Vice President of Carrington’s newly formed Veterinary Medical Division, stated, “I have been involved with Carrington products formulated and cleared by the U.S. Food and Drug Administration (FDA) to market for human decubitus and other ulcers since 1984. With results obtained with Carrington(R) human wound care products, I knew within reason that results in horses should be very good, but I did not expect the fantastic results we have seen as evidenced by our clinical studies (photograph example included). I have been extremely pleased. Veterinarians have reported much better control of hyper-granulation tissue. We were positively mentioned by the speakers at the American Association of Equine Practioners in San Antonio, Texas and at the North American Veterinary Conference in Orlando, Florida.”
Meares continued, “We now have seven representatives, with plans to have ten in place by the end of this year, who are calling directly on veterinarians and working with the leading equine distributors in North America. The EquineVet(TM) Acemannan Advanced Wound Therapy System products are now being stocked by major veterinary professional distributors. We have invited all veterinarians involved with horses to evaluate these Carrington products in their practices.”
About the EquineVet(TM) Acemannan Advanced Wound Therapy System
Carrington developed the EquineVet(TM) Acemannan Wound Therapy System which includes EquineVet(TM) Acemannan Smart Gel, EquineVet(TM) EquineGinate(TM) Acemannan Calcium Alginate and CarraSorb(TM) FDG Acemannan Freeze-Dried Gel. These products assist in the management of wound healing at each phase in the wound healing process. The products also help control fluids in wounds to provide the optimum moist wound environment. This moist wound environment is beneficial for production of autologous growth factors (cytokines) and maintenance of naturally-occurring growth factors essential for cell development, enables better macrophage activation and assists with autolytic debridement of the wound surface. Early results indicate that wounds are indeed exhibiting much less hyper-granulation (proud flesh) with use of these products.
Another very important part of wound care is wound cleansing, and Carrington has introduced two wound cleansers, EquineVet(TM) Acemannan Wound Cleanser and EquineVet(TM) Antimicrobial Wound Cleanser . These wound cleansers are non-irritating, modify surface tension for easy removal of debris and provide an optimal stream spray of approximately 12 P.S.I. The antimicrobial cleanser helps control and/or prevent infection while cleansing, and the Acemannan wound cleanser cleanses while introducing Acemannan to the wound environment.
About Carrington
Carrington Laboratories, Inc., is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington’s DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington’s technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company’s management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company’s filings with the Securities & Exchange Commission, including the Form 10-Q, filed November 14, 2006.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070330/DAF016-Ahttp://www.newscom.com/cgi-bin/prnh/20070330/DAF016-BAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCarrington Laboratories, Inc.
CONTACT: Kirk Meares, Vice President of Carrington Laboratories, Inc.,+1-972-518-1300
Web site: http://www.carringtonlabs.com/
